Charles River Laboratories and Toxys Announce Collaboration to Advance Non-Animal Developmental Toxicity Testing with ReproTracker
Reuters
Oct 08
Charles River Laboratories and Toxys Announce Collaboration to Advance Non-Animal Developmental Toxicity Testing with ReproTracker
Charles River Laboratories International Inc. has announced a collaboration with Toxys to enhance developmental and reproductive toxicology (DART) testing using New Approach Methodologies (NAMs). Through this partnership, Charles River's clients will gain access to ReproTracker, a human stem cell-based in vitro assay that identifies developmental toxicity hazards of new drugs and chemicals. The collaboration aims to accelerate the adoption and validation of ReproTracker as a non-animal alternative to traditional in vivo approaches, supporting the 3Rs principles of Replacement, Reduction, and Refinement in toxicology testing while maintaining high safety standards for patients and consumers.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charles River Laboratories International Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251008659993) on October 08, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.